Desvenlafaxine for the treatment of major depressive disorder

SG Kornstein, RS McIntyre, ME Thase… - Expert opinion on …, 2014 - Taylor & Francis
Introduction: Major depressive disorder (MDD) is a chronic and debilitating condition often
characterized by inadequate treatment. Notwithstanding the availability of more than a …

Efficacy and tolerability of desvenlafaxine in the real-world treatment of patients with major depression: a narrative review and an expert opinion paper

G Sampogna, F Caraci, C Carmassi… - Expert Opinion on …, 2023 - Taylor & Francis
Introduction Major depressive disorder (MDD) is a common severe mental disorder,
requiring a tailored and integrated treatment. Several approaches are available including …

Efficacy of desvenlafaxine compared with placebo in major depressive disorder patients by age group and severity of depression at baseline

D Mosca, M Zhang, R Prieto… - Journal of Clinical …, 2017 - journals.lww.com
Purpose This post hoc meta-analysis evaluated the efficacy and safety of desvenlafaxine 50
and 100 mg versus placebo across age groups and severity of depression at baseline in …

[HTML][HTML] Safety and effectiveness of desvenlafaxine in korean patients with major depressive disorder: a 6-month postmarketing surveillance study

S Roh, KS Lee, S Choi, JM Kim - Clinical Psychopharmacology …, 2022 - ncbi.nlm.nih.gov
Objective Although the safety and efficacy of desvenlafaxine have been demonstrated, long-
term evidence in Asians is lacking. We examined the safety and effectiveness of …

Adherence to Desvenlafaxine Versus Usual Care and Its Impact on Health Outcomes: A Comparative Real-world Clinical Study

N Cardoner, A Sicras-Mainar, J Rejas… - Clinical Drug …, 2021 - Springer
Abstract Background and Objective Low adherence to treatment is associated with poorer
clinical outcome and greater healthcare resources utilization (HRU). Limited data are …